06/30/2017

Telotristat ethyl update in NCCN Guidelines

Telotristat ethyl marketed as XERMELO™ 250 mg tid has been included as a recommended treatment option (category 2A) in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for neuroendocrine tumors (NETs.)^a

Telotristat ethyl has also been included in the NCCN Drugs & Biologics Compendium (NCCN Compendium)^b, with the following recommended use: “Consider in combination with octreotide or lanreotide for persistent diarrhea due to poorly controlled carcinoid syndrome; If disease progression, telotristat may be continued for persistent diarrhea in combination with octreotide or lanreotide and any of the subsequent treatment options.”

^a https://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf

^b https://www.nccn.org/professionals/drug_compendium/MatrixGenerator/Matrix.aspx?AID=462